Intravesical BCG+interferon-α-2b in prevention of recurrence in transitional cell carcinoma of urinary bladder
Bladder malignancy is the 11th most common cancer in the world with more than 2,00,000 new cases diagnosed every year 90% of these are TCC, of which 75-80% are superficial in nature. Our aim in this study was to find the efficacy, safety and cost effectiveness of a low dose intravesical imnumo-thera...
Main Authors: | Nayan K Mohanty, M N Mandal, A N Sinha, Alok K Jha |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2000-01-01
|
Series: | Indian Journal of Urology |
Subjects: | |
Online Access: | http://www.indianjurol.com/article.asp?issn=0970-1591;year=2000;volume=16;issue=2;spage=129;epage=133;aulast=Mohanty |
Similar Items
-
The comparative study of the effectiveness of BCG and Alfa-Interferon in preventing the recurrence of bladder tumor
by: Ghazimoghadam B (MD), et al.
Published: (1999-05-01) -
Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with <i>GMCSF+IFN α </i> Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model
by: Sin Mun Tham, et al.
Published: (2021-11-01) -
Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
by: Suresh Bhat, et al.
Published: (2015-01-01) -
Polymorphism in the First Intron of Interferon-Gamma Gene (+874T/A) in Patients with BCG Adenitis
by: N Parvaneh, et al.
Published: (2009-09-01) -
Polymorphism in the First Intron of Interferon-Gamma Gene (+874T/A) in Patients with BCG Adenitis
by: N Parvaneh, et al.
Published: (2009-09-01)